UBS Group Begins Coverage on Bruker (NASDAQ:BRKR)

Investment analysts at UBS Group began coverage on shares of Bruker (NASDAQ:BRKR) in a research report issued on Wednesday, Briefing.com reports. The brokerage set a “neutral” rating and a $65.00 price target on the medical research company’s stock. UBS Group’s price target would indicate a potential upside of 11.36% from the company’s current price.

A number of other brokerages have also recently commented on BRKR. Stifel Nicolaus set a $50.00 price objective on Bruker in a research note on Wednesday, August 5th. Zacks Research lowered Bruker from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Wolfe Research began coverage on Bruker in a report on Monday, June 1st. They issued a “peer perform” rating for the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research note on Monday, August 31st. Finally, Citigroup decreased their target price on Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $57.00.

Bruker Stock Down 0.2%

Shares of BRKR opened at $58.37 on Wednesday. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The company has a 50-day moving average price of $58.70 and a two-hundred day moving average price of $49.00. Bruker has a 12 month low of $30.09 and a 12 month high of $65.30. The stock has a market cap of $8.89 billion, a price-to-earnings ratio of -83.39, a P/E/G ratio of 1.79 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the business posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts predict that Bruker will post 2.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Bruker

A number of large investors have recently bought and sold shares of BRKR. Orbis Allan Gray Ltd increased its stake in Bruker by 5.4% during the 4th quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock valued at $702,256,000 after purchasing an additional 761,258 shares in the last quarter. Pallas Capital Advisors LLC bought a new position in shares of Bruker in the second quarter valued at approximately $570,746,000. California State Teachers Retirement System increased its position in shares of Bruker by 5,982.2% during the 2nd quarter. California State Teachers Retirement System now owns 7,455,459 shares of the medical research company’s stock valued at $448,670,000 after purchasing an additional 7,332,880 shares during the last quarter. State Street Corp raised its position in Bruker by 2.5% in the fourth quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock worth $180,700,000 after acquiring an additional 91,706 shares during the period. Finally, AQR Capital Management LLC increased its position in Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after buying an additional 1,850,215 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.